Obesity Update: Wegovy’s 7.2mg Bid, Rhythm’s Oral Win, TRPV1 Breakthrough & More
In this week’s Obesity Updates, we spotlight the most compelling developments transforming the obesity treatment landscape—from high-dose GLP-1 submissions and oral therapy breakthroughs to biotech funding rounds and international expansions.
🔬 Key Highlights This Week:
💉 Novo Nordisk seeks EMA approval for 7.2 mg Wegovy after 21% average weight loss in trials
📈 Rhythm Pharmaceuticals posts Phase II data: up to 9.3% BMI drop with oral bivamelagon
🧬 Yuhan deepens obesity R&D with new GLP-1 partnerships and GPCR targets
🧪 MetaVia doses 48 mg cohort of DA-1726, a dual GLP-1/glucagon receptor agonist
💊 Pila Pharma raises SEK 20M to develop first oral TRPV1-based obesity therapy
🇨🇦 Allurion expands into Canada with swallowable gastric balloon and digital support tools
Whether you’re a researcher, investor, or health leader, this episode offers a concise, expert-curated view of the most impactful updates in obesity innovation.
📢 Stay Ahead in Obesity Research!
✅ Like, share, and subscribe for weekly updates
#ObesityResearch #Wegovy #GLP1 #Bivamelagon #TRPV1 #MetaVia #PilaPharma #Allurion #ClinicalTrials #WeightLossInnovation #HealthcareConsulting #LucidQuest #MetabolicHealth #PharmaNews #BiotechUpdate